BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38881877)

  • 1. Integrated pan-cancer analysis reveals the immunological and prognostic potential of RBFOX2 in human tumors.
    Huang F; Jin L; Zhang X; Wang M; Zhou C
    Front Pharmacol; 2024; 15():1302134. PubMed ID: 38881877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
    Liu C; Zhang W; Zhou X; Liu L
    Front Immunol; 2022; 13():983490. PubMed ID: 36618420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifies microtubule-binding protein
    Wang W; Zhang J; Wang Y; Xu Y; Zhang S
    Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
    Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
    Front Immunol; 2022; 13():903461. PubMed ID: 35663977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 8. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 13. A Comprehensive Pan-Cancer Analysis Reveals Cyclin-Dependent Kinase Inhibitor 2A Gene as a Potential Diagnostic and Prognostic Biomarker in Colon Adenocarcinoma.
    Salem A; Ahmed S; Khalfallah M; Hamadan N; ElShikh W; Alfaki M
    Cureus; 2024 May; 16(5):e60586. PubMed ID: 38894777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
    Yang W; Liu Z; Liu T
    Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of
    Fei L; Lu Z; Xu Y; Hou G
    Front Genet; 2022; 13():920897. PubMed ID: 36035140
    [No Abstract]   [Full Text] [Related]  

  • 18. Pan-cancer analysis of necroptosis-related gene signature for the identification of prognosis and immune significance.
    Ma J; Jin Y; Gong B; Li L; Zhao Q
    Discov Oncol; 2022 Mar; 13(1):17. PubMed ID: 35312867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of NCS1 in Immunotherapy and Prognosis of Human Cancer.
    Wang GC; Gan X; Zeng YQ; Chen X; Kang H; Huang SW; Hu WH
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Molecular Characterization of m
    Zhu J; Xiao J; Wang M; Hu D
    Front Oncol; 2020; 10():618374. PubMed ID: 33585244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.